Article
28 Apr 2025
Charting A Conditional Approval Pathway For Rare Disease Drugs – A Top Priority For A Revamped FDA?
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
04 Apr 2025
A Look Ahead In Life Sciences: What We Are Tracking In The Second Quarter Of 2025 And Beyond
Article
28 Feb 2025
Goodwin's 2025 Rare Disease Symposium: Momentum Builds For Addressing Critical Diagnosis And Treatment Gaps
Article
27 Jan 2025
How The Trump Administration Could Reshape Regulation In The Life Sciences Sector
Article
10 Jan 2025
Changes Expected As Trump Administration Continues To Take Shape
Article
07 Nov 2024
New Momentum For A Time-Limited Conditional Approval Pathway For Rare Disease Drugs
Article
03 Oct 2024
A Look Ahead In Life Sciences: What We Are Tracking In The Fourth Quarter Of 2024 And Beyond
Article
25 Jul 2024
Common FDA Bioresearch Monitoring (BIMO) Violations: Updates From FY 2023 To Now
Article
01 Jul 2024
FDA Issues Overdue Draft Guidance On Clinical Trial Diversity Action Plans
Article
10 Jun 2024
Form FDA 483 Response Best Practices Announced By The FDA